HOME / BMST-MINISITE-APOQUEL
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Important Safety Information
Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infections or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.
For more information, please see the full Prescribing Information.
References: 1. Data on file. Study report A161R-AU-12-096. 2013. Zoetis Inc. 2. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114.3. Data on file. Study report 1962C-60-11-A75. 2013. Zoetis Inc. 4. Gonzales A, Bowman J, Fici G, Zhang M, Mann D, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. In press. 5. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297.
All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors.
APQ-00073 ©2014 Zoetis Inc. All rights reserved. September 2014.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States